This bill requires physicians and osteopathic doctors in West Virginia to complete continuing education credits specifically in nutrition as part of their biennial license renewal process. The law mandates that medical professionals earn a minimum of fifty hours of continuing medical education every two years, with osteopathic physicians required to complete thirty-two hours including nutrition training, and these credits must be approved by relevant medical boards. The bill amends existing state code sections to make nutrition education a mandatory component of the continuing education requirement for license renewal.
HB 4610 allows terminally ill patients in West Virginia to access experimental, individually tailored medical treatments (like gene therapies) when standard FDA-approved options have been exhausted. It defines "eligible patients" as those with life-threatening illnesses who have consulted a physician, considered all approved treatments, and provided written consent detailing treatment risks and alternatives. Key provisions require healthcare providers to document patient eligibility, obtain specific informed consent covering potential outcomes, and prohibit debt collection from estates if a patient dies during treatment. The bill also protects healthcare providers from sanctions for offering these treatments and clarifies that it does not affect health insurers' obligations to cover clinical trial participation.
HB 5277 is a funding bill that allocates $1 million to Welch Community Hospital, $3.4 million to William R. Sharpe Jr. Hospital, and $4.3 million to Mildred Mitchell-Bateman Hospital from West Virginia's unappropriated surplus balance. These funds are designated specifically for capital improvements, repairs, and equipment at each hospital during fiscal year 2026. The bill supplements existing appropriations by adding these new funding lines to the hospitals' respective budgets. It directly affects the three named hospitals by providing additional resources for facility maintenance and infrastructure. The bill does not create new policies or programs but reallocates existing surplus funds for capital purposes.
This bill increases funding for West Virginia's Children's Health Insurance Program (CHIP) by adding $422,562 for administrative costs and $449,429 for services under fund 0403. It supplements existing appropriations using an unappropriated balance from the State Fund, General Revenue, to support CHIP operations during fiscal year 2026. The funding directly affects CHIP beneficiaries and program administrators by providing additional resources for program management and services. This is a procedural budget adjustment, not a policy change, and it applies to the fiscal year ending June 30, 2026.
SB 844 is a supplemental funding bill that allocates additional federal funds to the West Virginia Department of Human Services for medical services. It increases existing appropriations for "Medical Services" (by $1.373 billion) and "Medical Services Administrative Costs" (by $37 million) under Fund 8722 for fiscal year 2026. This funding uses unspent federal moneys designated for the state's medical programs, directly supporting the department's operations for healthcare services. The bill does not create new programs but adjusts how existing federal funds are applied to current medical service expenditures.
SB 848 is a supplemental appropriation bill that allocates $84,600 from an unappropriated surplus balance in the State Fund, General Revenue, to cover inmate medical expenses for the Division of Corrections and Rehabilitation under the Department of Homeland Security during fiscal year 2026. This funding specifically targets Correctional Units within the Division and uses existing surplus funds identified in the Governor’s budget document. The bill does not create new programs or alter policies but directs available resources to address medical costs for inmates. It is a routine budget adjustment, not a policy change, to ensure necessary healthcare funding for correctional facilities.
SB 819 redirects $4,906,630 from an unappropriated surplus balance in West Virginia's General Revenue Fund to William R. Sharpe Jr. Hospital (fund 0413) for fiscal year 2026. The bill supplements the hospital's existing appropriation by adding a new line item for "Current Expenses - Surplus" to cover operational costs. This procedural budget adjustment directly affects the hospital's funding for the 2026 fiscal year without changing health care policies or creating new obligations. The funds were identified in the Governor's Executive Budget Document as available surplus.
SB 897 establishes licensing and certification requirements for alcohol and drug counselors in West Virginia. It defines key terms like "substance use disorder" and "practice of alcohol and drug counseling," which includes evaluating addiction issues, developing treatment plans, and providing trauma-informed care. The bill sets eligibility criteria, application fees, renewal fees, and grandfathering provisions for existing counselors based on education or experience. It also creates disciplinary actions for violations and specifies exceptions for healthcare providers, state employees, and self-help groups. This bill directly affects counselors seeking to provide substance use disorder treatment services in the state.
SB 741 expands the pilot program for involuntary commitment processes to include additional counties: Cabell, Berkeley, Hampshire, Morgan, Ohio, and Wood. The bill requires mental health centers in these counties to provide timely evaluations (in-person or via video) for potential commitment and explain the process to affected individuals. It also mandates quarterly audits of commitment applications to ensure clinical justification, with findings kept confidential. This bill directly affects mental health centers, courts, law enforcement, and individuals subject to involuntary commitment in the expanded counties.
This bill allows doctors in West Virginia to legally prescribe, distribute, and market specific forms of psilocybin once the FDA approves it and the DEA reschedules it. It amends state pharmacy laws to remove barriers for FDA-approved crystalline polymorph psilocybin products, aligning state regulations with federal decisions. The law applies only to pharmaceutical compositions of psilocybin that meet federal approval standards, not to raw or unapproved forms of the substance. Healthcare providers and pharmacies would be able to handle these medications under existing prescription drug frameworks once federal requirements are met.